
Living therapy: Microbial immunotherapy of Exeliom Biosciences gets a boost
Exeliom Biosciences (Paris, France) is using its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies....

Biomethane fuel offers negative carbon footprint
German scientists at the University of Hohenheim have reported that fuels made from agricultural residues can even have a negative CO2 impact on bus...

Mystery solved: Mysthera Theapeutics launches with $3.5m
Mysthera Therapeutics AG was just founded in Basel, Switzerland by Forty51 Ventures with $3.5m seed capital. Pursuing a first-in-class...

SeaBeLife secures €1.2m in funding
SeaBeLife SAS has secured €1.2m in funding, aiming to develop unique drug candidates that block cell necrosis and target two regulated cell death...

Pairwise and Bayer collaborate to CRISPR short-stem maize
Following Leaps by Bayer's co-investment in a US$90m Series B financing in Pairwise Plants Services Inc. in 2021,German seed giant Bayer AG has...

Neuraxpharm pays US$650m for MS drug commercialisation
Together with a fee of US$12.5m for the launch of the B cell suppressant antibody to treat relapsing/remitting mulitple sclerosis (rMS), the US$140m...

Oxford Biomedica expands agreement with Cabaletta Bio
Philadelphia-based clinical-stage biotech Cabaletta Bio focuses on developing and launching the first curative targeted cell therapies for patients...